The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations)

Authors:

Razumova I.Yu., Godzenko A.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(3): 68‑72

DOI: 10.17116/oftalma202213803168

Read: 3774 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN THE TREATMENT OF UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (CLINICAL OBSERVATIONS)
GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN THE TREATMENT OF UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (CLINICAL OBSERVATIONS)

To cite this article:

Razumova IYu, Godzenko AA. Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations). Russian Annals of Ophthalmology. 2022;138(3):68‑72. (In Russ., In Engl.)
https://doi.org/10.17116/oftalma202213803168

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95
Abstract:

The article describes clinical cases with effective use of some genetically engineered biological agents for arresting and preventing uveitis attacks, and discusses the potential usage of tumor necrosis factor (TNF)-alpha inhibitors and interleukin-17 inhibitors in the treatment of uveitis in patients with ankylosing spondylitis.

Keywords:

uveitis
ankylosing spondylitis
TNF-alpha inhibitors
IL17-inhibitors

Authors:

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Received:

18.06.2021

Accepted:

15.02.2022

Close metadata

References:

  1. Erdes SF, Badokin VV, Bochkova AG, Bugrova OV, Gaidukova IZ, et al. On the Terminology of Spondyloarthritis. Rheumatology Science and Practice = Nauchno-prakticheskaya revmatologiya. 2015;53(6):657-660. (In Russ). https://doi.org/10.14412/1995-4484-2015-657-660
  2. Brewerton DA, Caffrey M, Nicholls A. Letter: Acute anterior uveitis and HLA-B27. Lancet. 1974;1(7855):464.  https://doi.org/10.1016/s0140-6736(74)92431-3
  3. Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol. 2010; 37(12):2606-2616. https://doi.org/10.3899/jrheum.100889
  4. Razumova IYu, Godzenko AA, Vorob’eva OK, Guseva IA. Uveitis in Spondyloarthritis patients and its association with HLA-B27 histocompatibility antigen: Prospective study. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2016;132(4):4-9. (In Russ.). https://doi.org/10.17116/oftalma 201613244-4
  5. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis; current concepts of pathogens and interactions with the spondyloarthropathies. Curr Opin Rheum. 2002;14(4):337-341.  https://doi.org/10.1097/00002281-00001
  6. Godzenko AA, Razumova IYu. Clinical features and treatment of uveitis in patients with ankylosing spondylitis. Effektivnaya farmakoterapiya (revmatologiya, travmatologiya i ortopediya). 2013;52(2):26-35. (In Russ.).
  7. Godzenko AA, Bochkova AG, Rumyantseva OA, Razumova IYu, Badokin VV, Erdes SF. Progression and outcomes of uveitis in patients with ankylosing spondylitis. Rheumatology Science and Practice = Nauchno-prakticheskaya revmatologiya. 2014;52(5):520-525. (In Russ.). https://doi.org/10.14412/1995-4484-2014-520-525
  8. Fernandes-Melon J, Munos-Fernandes S, Hidalgo V, Bonilla-Hernan G, Schlincker A, Fonceca A, Veitez J, Martin-Mola E. Uveitis as the Initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol. 2004;31(3):524-527. 
  9. Zeidler H, Amor B. The Assesment in Spondyloarthritis International Society (ASAS) Classification Criteria for Spondyloarthritis in General: The Spondyloarthritis Concept in Progress. Ann Rheum Dis. 2011;70(1):1-3.  https://doi.org/10.1136/frd.2010/135889
  10. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Brezin AP, Chee SP, Devis JL, Ramanan A, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology American Academy of Ophthalmology Fundamentals of Care for Uveitis (FOCUS). Ophthalmology. 2018;125(5):757-773. Epub 2018 Jan 6.  https://doi.org/10.1016/J ophtha 2017.11.017
  11. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc V, Duclos M, Dugados M. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631-1663. https://doi.org/10.1136/ard 2006.052092
  12. Lim LL, Fraunfelder FW, Rosenbaum JT. Do Tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10): 3248-3252. https://doi.org/10.1002/art 22918
  13. Heslinga SC, Nurmohamed MT, Gerarde AH, Griep E, Koehorst C, Kok MR, Schilder A, Verhoef M, Van der Horst-Bruinsma IE. Significantly reduced recurrence rate of acute anterior uveitis in ankylosing spondelitis during treatment with golimumab. Arthritis Rheum. 2016;68(10). Annual Meeting.
  14. Calvo-Río V, Blanco R, Santos-Gomes M, Rubio-Romero E, Cordero-Coma M, Gallergo-Flores A, Veroz R, Torre I, Hernandez FF, Atanes A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101.  https://doi.org/10.1016/j.semarthrit 2016.03.002
  15. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070-1077. https://doi.org/10.1136/anrheumdis-2016-209730
  16. Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Gupta AD, Martin R, Safi J, Porter B, Shete A, Rosenbaum JT. Incidence of Uveitis in Secukinumab-treated Patients with Ankylosing Spondylitis: Pooled Data Analysis from Three Phase 3 Studies ACR. Open Rheumatol. 2020;2(5):294-299.  https://doi.org/10.1002/acr2.11139
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.